Source link : https://www.newshealth.biz/health-news/limited-stage-sclc-gets-a-new-standard-of-care-with-consolidation-durvalumab/
CHICAGO — Consolidation treatment with durvalumab (Imfinzi) following concurrent chemoradiotherapy significantly improved both overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (SCLC), the phase III randomized ADRIATIC trial showed. Median OS was 55.9 months in the durvalumab group compared with 33.4 months in the placebo group (HR 0.73, […]
Author : News Health
Publish date : 2024-06-03 19:43:24
Copyright for syndicated content belongs to the linked Source.
Categories